Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

1.

Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections.

Weiss K, Allgren RL, Sellers S.

Clin Infect Dis. 2012 Aug;55 Suppl 2:S110-5. doi: 10.1093/cid/cis390. Review.

PMID:
22752858
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.

Crawford T, Huesgen E, Danziger L.

Am J Health Syst Pharm. 2012 Jun 1;69(11):933-43. doi: 10.2146/ajhp110371. Review.

PMID:
22610025
[PubMed - indexed for MEDLINE]
3.

Fidaxomicin versus vancomycin for Clostridium difficile infection.

Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK; OPT-80-003 Clinical Study Group.

N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812.

PMID:
21288078
[PubMed - indexed for MEDLINE]
Free Article
4.

Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.

Lancaster JW, Matthews SJ.

Clin Ther. 2012 Jan;34(1):1-13. doi: 10.1016/j.clinthera.2011.12.003. Review.

PMID:
22284993
[PubMed - indexed for MEDLINE]
5.

Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.

Sullivan KM, Spooner LM.

Ann Pharmacother. 2010 Feb;44(2):352-9. doi: 10.1345/aph.1M351. Epub 2010 Jan 13. Review.

PMID:
20071495
[PubMed - indexed for MEDLINE]
6.
7.

Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.

Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, Miller MA, Esposito R, Louie TJ, Stoesser NE, Young BC, Angus BJ, Gorbach SL, Peto TE; Study 003/004 Teams.

Clin Infect Dis. 2012 Aug;55 Suppl 2:S93-103. doi: 10.1093/cid/cis499.

PMID:
22752871
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections.

Soriano MM, Liao S, Danziger LH.

Expert Rev Anti Infect Ther. 2013 Aug;11(8):767-76. doi: 10.1586/14787210.2013.814767.

PMID:
23977933
[PubMed - indexed for MEDLINE]
9.

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?

Cornely OA.

Clin Microbiol Infect. 2012 Dec;18 Suppl 6:28-35. doi: 10.1111/1469-0691.12012. Review.

PMID:
23121552
[PubMed - indexed for MEDLINE]
10.

Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.

Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W.

Clin Infect Dis. 2012 Aug;55 Suppl 2:S132-42. doi: 10.1093/cid/cis338.

PMID:
22752862
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Fidaxomicin, a new treatment for Clostridium difficile infections.

Epstein L, Golan Y.

Drugs Today (Barc). 2012 Feb;48(2):101-8. doi: 10.1358/dot.2012.48.2.1746740. Review.

PMID:
22384450
[PubMed - indexed for MEDLINE]
12.

Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.

Hardesty JS, Juang P.

Pharmacotherapy. 2011 Sep;31(9):877-86. doi: 10.1592/phco.31.9.877. Review.

PMID:
21923589
[PubMed - indexed for MEDLINE]
13.

Fidaxomicin for the treatment of Clostridium difficile infections.

Whitman CB, Czosnowski QA.

Ann Pharmacother. 2012 Feb;46(2):219-28. doi: 10.1345/aph.1Q481. Epub 2012 Feb 7. Review.

PMID:
22318930
[PubMed - indexed for MEDLINE]
14.

Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection.

Venugopal AA, Johnson S.

Clin Infect Dis. 2012 Feb 15;54(4):568-74. doi: 10.1093/cid/cir830. Epub 2011 Dec 7. Review.

PMID:
22156854
[PubMed - indexed for MEDLINE]
Free Article
15.

Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.

Miller M.

Expert Opin Pharmacother. 2010 Jun;11(9):1569-78. doi: 10.1517/14656566.2010.485614. Review.

PMID:
20446864
[PubMed - indexed for MEDLINE]
16.

Clostridium difficile infection in older adults: a review and update on its management.

Kee VR.

Am J Geriatr Pharmacother. 2012 Feb;10(1):14-24. doi: 10.1016/j.amjopharm.2011.12.004. Epub 2012 Jan 20. Review.

PMID:
22260856
[PubMed - indexed for MEDLINE]
17.

Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.

Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL.

Clin Infect Dis. 2012 Aug;55 Suppl 2:S154-61. doi: 10.1093/cid/cis462.

PMID:
22752865
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.

Tannock GW, Munro K, Taylor C, Lawley B, Young W, Byrne B, Emery J, Louie T.

Microbiology. 2010 Nov;156(Pt 11):3354-9. doi: 10.1099/mic.0.042010-0. Epub 2010 Aug 19.

PMID:
20724385
[PubMed - indexed for MEDLINE]
Free Article
19.

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.

Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S; OPT-80-004 Clinical Study Group.

Lancet Infect Dis. 2012 Apr;12(4):281-9. doi: 10.1016/S1473-3099(11)70374-7. Epub 2012 Feb 8.

PMID:
22321770
[PubMed - indexed for MEDLINE]
20.

Role of fidaxomicin for the treatment of Clostridium difficile infection.

Juang P, Hardesty JS.

J Pharm Pract. 2013 Oct;26(5):491-7. doi: 10.1177/0897190013499526.

PMID:
24064437
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk